Comment on the Article by Dutra Medeiros et al. Entitled �Dexamethasone Intravitreal Implant for Treatment of Patients with Persistent Diabetic Macular Edema'

2015 ◽  
Vol 233 (2) ◽  
pp. 117-118 ◽  
Author(s):  
M�cella Arikan Yorgun ◽  
Yasin Toklu
Keyword(s):  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Dexamethasone Intravitreal Implant ◽  
Intravitreal Implant ◽  
Persistent Diabetic Macular Edema

Dexamethasone Intravitreal Implant for Treatment of Patients with Persistent Diabetic Macular Edema

2014 ◽  
Vol 231 (3) ◽  
pp. 141-146 ◽  
Author(s):  
Marco Dutra Medeiros ◽  
Maurizio Postorino ◽  
Rafael Navarro ◽  
José Garcia-Arumí ◽  
Carlos Mateo ◽  
...  
Keyword(s):  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Dexamethasone Intravitreal Implant ◽  
Intravitreal Implant ◽  
Persistent Diabetic Macular Edema

Dexamethasone Intravitreal Implant in Combination with Laser Photocoagulation for the Treatment of Diffuse Diabetic Macular Edema

Ophthalmology ◽  
2013 ◽  
Vol 120 (9) ◽  
pp. 1843-1851 ◽  
Author(s):  
David G. Callanan ◽  
Sunil Gupta ◽  
David S. Boyer ◽  
Thomas A. Ciulla ◽  
Michael A. Singer ◽  
...  
Keyword(s):  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Laser Photocoagulation ◽  
Dexamethasone Intravitreal Implant ◽  
Intravitreal Implant ◽  
Diffuse Diabetic Macular Edema

Rapid response to dexamethasone intravitreal implant in diabetic macular edema

2017 ◽  
Vol 28 (1) ◽  
pp. 74-79 ◽  
Author(s):  
Giuseppe Lo Giudice ◽  
Antonio Avarello ◽  
Gianluca Campana ◽  
Alessandro Galan
Keyword(s):  
Visual Acuity ◽  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Secondary Outcome ◽  
Dexamethasone Intravitreal Implant ◽  
Clinical Series ◽  
Intravitreal Implant ◽  
Early Effects ◽  
Sd Oct

Purpose: To evaluate the early effects of dexamethasone (DEX) intravitreal implants in patients with diabetic macular edema (DME). Methods: This was a prospective, single-arm, interventional clinical series. Eighteen patients (18 eyes) with chronic/recalcitrant or naive DME were included. Patients underwent single DEX intravitreal implant. Clinical assessments, including ophthalmologic examination, central retinal thickness (CRT) measurement by spectral-domain optical coherence tomography (SD-OCT) scan, best-corrected visual acuity (BCVA), and intraocular pressure (IOP) were carried out at baseline, 1-3 hours, and then 3, 7, and 30 days after treatment. The main outcome was change in CRT on SD-OCT, while secondary outcome measures included visual acuity (VA) and changes in IOP following implant. Results: Mean CRT significantly decreased from 565 ± 171 µm at baseline to 310 ± 89 µm at end of follow-up (p<0.001), with reduction becoming evident 1-3 hours after injection. Mean BCVA also significantly improved 7 days and 30 days after treatment up to 0.14 logMAR (p<0.05). All patients had a controlled IOP after the injection with only 1/18 eyes having a transient increase in IOP during follow-up. Conclusions: This is the first study showing very early effects of DEX implants on CRT reduction and VA improvement in DME.

Dexamethasone Intravitreal Implant at the Time of Cataract Surgery in Eyes with Diabetic Macular Edema

2016 ◽  
Vol 27 (4) ◽  
pp. 433-437 ◽  
Author(s):  
Giacomo A. Panozzo ◽  
Elena Gusson ◽  
Giorgio Panozzo ◽  
Giulia Dalla Mura
Keyword(s):  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Foveal Thickness ◽  
Dexamethasone Intravitreal Implant ◽  
Positive Effects ◽  
Intravitreal Implant ◽  
A Prospective Study

Purpose To determine the potential role of intraoperative dexamethasone intravitreal implant (DEX-I) in reducing diabetic macular edema (DME) worsening after phacoemulsification. Methods This was a prospective study on 19 eyes of 19 patients with type 2 diabetes mellitus with DME and cataract. Mean preoperative Early Treatment Diabetic Retinopathy Study visual acuity (VA) was 16.7 letters. Mean foveal thickness (FT) was 451 μm. The DME was naive in 11 eyes and refractory in 8 eyes. All eyes underwent a standard phacoemulsification and intraocular lens implantation; DEX-I was injected at the end of surgery. Follow-up was performed at 1 week and then monthly until DME recurrence (up to 8 months). Results At 1 week, mean VA improved by 15 letters (range 0-29 letters) and mean FT decreased by 147 μm (range 69-236 μm). Improvement consolidated at month 1, with a mean VA improvement of 18 letters (range 3-32 letters) and a mean improvement in FT of 193 μm (range 76-304 μm), remaining stable at month 2 after surgery in all eyes. The DME recurred in 1 eye at month 3, in 14 eyes (73.8%) between months 4 and 5, and after month 6 in 4 eyes (21%). Refractory DMEs demonstrated the same benefit but recurred earlier than naive ones (4 months versus 5.8 months, p<0.01). Conclusions Intraoperative DEX-I prevents DME worsening after phacoemulsification. Its positive effects last for at least 3 months.

Efficacy of Dexamethasone Intravitreal Implant for the Treatment of Diabetic Macular Edema

2015 ◽  
Vol 25 (5) ◽  
pp. 448-453 ◽  
Author(s):  
Sophie Bonnin ◽  
Bénédicte Dupas ◽  
Mohamed El Sanharawi ◽  
Julien Perol ◽  
Ali Erginay ◽  
...  
Keyword(s):  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Dexamethasone Intravitreal Implant ◽  
Intravitreal Implant
Sign in / Sign up

Export Citation Format

Share Document